HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $20.88 Average PT from Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned a consensus rating of “Hold” from the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.8750.

Several equities research analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Wednesday, October 8th. Zacks Research lowered HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 9th. Morgan Stanley cut HUTCHMED from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $18.00 to $13.75 in a report on Monday, September 22nd. Finally, Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th.

Hedge Funds Weigh In On HUTCHMED

Hedge funds have recently made changes to their positions in the stock. ABN Amro Investment Solutions acquired a new stake in shares of HUTCHMED during the 2nd quarter worth $962,000. Vanguard Personalized Indexing Management LLC grew its position in HUTCHMED by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after acquiring an additional 2,916 shares during the period. Goldman Sachs Group Inc. increased its stake in HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after acquiring an additional 7,342 shares during the last quarter. Vident Advisory LLC increased its stake in HUTCHMED by 78.3% during the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock worth $297,000 after acquiring an additional 8,664 shares during the last quarter. Finally, Tema Etfs LLC purchased a new position in shares of HUTCHMED in the 2nd quarter worth about $641,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Performance

Shares of HCM opened at $13.48 on Wednesday. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $19.50. The company’s 50 day simple moving average is $14.48 and its 200 day simple moving average is $15.64. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.